Literature DB >> 1970670

Psychotogenic drug use and neuroleptic response.

M B Bowers1, C M Mazure, J C Nelson, P I Jatlow.   

Abstract

When fixed doses of haloperidol or perphenazine were used in two separate studies, we found that psychotic males with a prior history of psychotogenic drug use had a poorer early neuroleptic response even in the early stages of their psychotic disorder than psychotic males who had not previously used significant amounts of psychotogenic drugs. Relative neuroleptic refractoriness may be characteristic of some dual diagnosis patients at the beginning of their illness. Antecedent psychotogenic drug use may contribute to the development of psychosis and to relative neuroleptic refractoriness by means of effects upon dopaminergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970670     DOI: 10.1093/schbul/16.1.81

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  21 in total

1.  Use of potentially abusive psychotropic substances in psychiatric inpatients.

Authors:  J Modestin; C Nussbaumer; K Angst; P Scheidegger; D Hell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

Review 2.  Substance abuse and schizophrenia: pharmacotherapeutic intervention.

Authors:  Alan I Green; Douglas L Noordsy; Mary F Brunette; Christopher O'Keefe
Journal:  J Subst Abuse Treat       Date:  2007-06-15

Review 3.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 4.  [Pharmacotherapy of schizophrenia and comorbid substance use disorder. A systematic review].

Authors:  T Wobrock; R D'Amelio; P Falkai
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

5.  Substance use reduction in the context of outpatient psychiatric treatment: a collaborative, motivational, harm reduction approach.

Authors:  K B Carey
Journal:  Community Ment Health J       Date:  1996-06

6.  [State-dependent motivational interviewing for people with schizophrenia and substance use: results of a randomised controlled trial].

Authors:  A Bechdolf; B Pohlmann; J Güttgemanns; C Geyer; K Lindner; C Ferber; E Gouzoulis-Mayfrank
Journal:  Nervenarzt       Date:  2012-07       Impact factor: 1.214

7.  Enhancing readiness-to-change substance abuse in persons with schizophrenia. A four-session motivation-based intervention.

Authors:  K B Carey; D M Purnine; S A Maisto; M P Carey
Journal:  Behav Modif       Date:  2001-07

8.  A comparison of schizophrenic patients with or without coexisting substance use disorder.

Authors:  Coreen Farris; Christiane Brems; Mark E Johnson; Rebecca Wells; Randall Burns; Nicholas Kletti
Journal:  Psychiatr Q       Date:  2003

Review 9.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Douglas L Noordsy; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2003-10       Impact factor: 5.285

10.  Developmental and neurologic correlates of treatment response in schizophrenia.

Authors:  C L Whelton; J M Cleghorn; S Atley; G J Durocher; D MacCrimmon
Journal:  J Psychiatry Neurosci       Date:  1992-03       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.